» Articles » PMID: 16755295

Established Breast Cancer Risk Factors by Clinically Important Tumour Characteristics

Overview
Journal Br J Cancer
Specialty Oncology
Date 2006 Jun 7
PMID 16755295
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is a morphologically and clinically heterogeneous disease; however, it is less clear how risk factors relate to tumour features. We evaluated risk factors by tumour characteristics (histopathologic type, grade, size, and nodal status) in a population-based case-control of 2386 breast cancers and 2502 controls in Poland. Use of a novel extension of the polytomous logistic regression permitted simultaneous modelling of multiple tumour characteristics. Late age at first full-term birth was associated with increased risk of large (> 2 cm) tumours (odds ratios (95% confidence intervals) 1.19 (1.07-1.33) for a 5-year increase in age), but not smaller tumours (P for heterogeneity adjusting for other tumour features (Phet) = 0.007). On the other hand, multiparity was associated with reduced risk for small tumours (0.76 (0.68-0.86) per additional birth; Phet = 0.004). Consideration of all tumour characteristics simultaneously revealed that current or recent use of combined hormone replacement therapy was associated with risk of small (2.29 (1.66-3.15)) and grade 1 (3.36 (2.22-5.08)) tumours (Phet = 0.05 for size and 0.0008 for grade 1 vs 3), rather than specific histopathologic types (Phet = 0.63 for ductal vs lobular). Finally, elevated body mass index was associated with larger tumour size among both pre- and postmenopausal women (Phet = 0.05 and 0.0001, respectively). None of these relationships were explained by hormone receptor status of the tumours. In conclusion, these data support distinctive risk factor relationships by tumour characteristics of prognostic relevance. These findings might be useful in developing targeted prevention efforts.

Citing Articles

Host, reproductive, and lifestyle factors in relation to quantitative histologic metrics of the normal breast.

Abubakar M, Klein A, Fan S, Lawrence S, Mutreja K, Henry J Breast Cancer Res. 2023; 25(1):97.

PMID: 37582731 PMC: 10426057. DOI: 10.1186/s13058-023-01692-7.


Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer.

Velenosi T, Krausz K, Hamada K, Dorsey T, Ambs S, Takahashi S NPJ Precis Oncol. 2022; 6(1):70.

PMID: 36207498 PMC: 9547066. DOI: 10.1038/s41698-022-00313-4.


Tumor-Associated Stromal Cellular Density as a Predictor of Recurrence and Mortality in Breast Cancer: Results from Ethnically Diverse Study Populations.

Abubakar M, Zhang J, Ahearn T, Koka H, Guo C, Lawrence S Cancer Epidemiol Biomarkers Prev. 2021; 30(7):1397-1407.

PMID: 33952648 PMC: 8254774. DOI: 10.1158/1055-9965.EPI-21-0055.


A mixed-model approach for powerful testing of genetic associations with cancer risk incorporating tumor characteristics.

Zhang H, Zhao N, Ahearn T, Wheeler W, Garcia-Closas M, Chatterjee N Biostatistics. 2020; 22(4):772-788.

PMID: 32112086 PMC: 8511944. DOI: 10.1093/biostatistics/kxz065.


Bayesian and Frequentist Analytical Approaches Using Log-Normal and Gamma Frailty Parametric Models for Breast Cancer Mortality.

Alotaibi R, Guure C Comput Math Methods Med. 2020; 2020:9076567.

PMID: 32089731 PMC: 7031729. DOI: 10.1155/2020/9076567.


References
1.
Jones B, Kasi S, Curnen M, Owens P, Dubrow R . Severe obesity as an explanatory factor for the black/white difference in stage at diagnosis of breast cancer. Am J Epidemiol. 1997; 146(5):394-404. DOI: 10.1093/oxfordjournals.aje.a009292. View

2.
. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1999; 350(9084):1047-59. View

3.
Hall H, Coates R, Uhler R, Brinton L, Gammon M, Brogan D . Stage of breast cancer in relation to body mass index and bra cup size. Int J Cancer. 1999; 82(1):23-7. DOI: 10.1002/(sici)1097-0215(19990702)82:1<23::aid-ijc5>3.0.co;2-e. View

4.
Gapstur S, Morrow M, Sellers T . Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA. 1999; 281(22):2091-7. DOI: 10.1001/jama.281.22.2091. View

5.
Yasui Y, Potter J . The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control. 1999; 10(5):431-7. DOI: 10.1023/a:1008970121595. View